A highly potent and specific URAT1 inhibitor with IC50 of 25 nM; displays 200-fold lower affinity for the related URAT1 homologs OAT4 and OAT1; reduces the sUA by up to 60% with a single 40 mg dose in healthy human volunteers, and increases the FEUA in a dose-dependent manner with EC50 of 22 nM; currently in phase 2 trials for the treatment of gout and asymptomatic hyperuricemia.Gout Phase 2 Clinical(In Vitro):Verinurad inhibits the transport activity of human URAT1 in a dose-dependent manner, at high potency with an IC50 of 25 nM.